Diagnosis and Treatment Pathway of MDR/RR-TB in Taizhou, Zhejiang Province, China
-
Published:2023-01-21
Issue:2
Volume:8
Page:79
-
ISSN:2414-6366
-
Container-title:Tropical Medicine and Infectious Disease
-
language:en
-
Short-container-title:TropicalMed
Author:
Lu Jingting12, Xu Yuanyuan3, Li Zhipeng14, Chen Xiaoxiao3, Lin Haijiang3, Zhao Qi12ORCID
Affiliation:
1. School of Public Health, Fudan University, Shanghai 200032, China 2. Key Laboratory of Public Health Safety, Ministry of Education, Shanghai 200032, China 3. Taizhou Center for Disease Control and Prevention, Zhejiang 318000, China 4. Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
Abstract
This study aims to understand MDR/RR-TB patients’ experience from seeking TB-related health care to diagnosis and treatment completion, as well as the social determinants with the waiting time for DST and treatment, pre-treatment attrition, and treatment outcome based on a retrospective cohort study. Univariate and multi-variate logistic regressions were used to analyze the associated factors. The median time of waiting time for DST and treatment was 24.00 and 30.00 days, respectively. Non-residential patients (aOR: 2.89, 95% CI: 1.14–7.70), registered before 2018 (aOR: 19.93, 95% CI: 8.99–48.51), first visited a county-level hospital (aOR: 4.65, 95% CI: 1.08–21.67), sputum smear-negative (aOR: 3.54, 95% CI: 1.28–10.16), and comorbid with pneumoconiosis (aOR: 7.10, 95% CI: 1.23–47.98) had a longer DST delay. The pre-treatment attrition was 26.9% (82/305). Elderly, non-residential patients and patients registered before 2018 were more likely to refuse MDR/RR treatment. However, in housekeeping/unemployment and farmer/fisherman, recurrent patients tended to take therapeutic measures actively. The successful treatment rate was 62.1% (105/169). Elderly, comorbidity with diabetes and sputum smear conversion time >1 month may lead to poorer outcomes. Immediate interventions should be taken to smooth diagnosis and treatment pathways and improve the social protections further so as to encourage patients to cooperate with the treatment actively.
Funder
Taizhou City Foundation
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology
Reference37 articles.
1. World Health Organization (2022). Global Tuberculosis Report 2022, WHO. Available online: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022. 2. World Health Organization (2020). Global Tuberculosis Report 2020, WHO. Available online: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf?ua=1. 3. Xu, C., Li, R., Shewade, H.D., Jeyashree, K., Ruan, Y., Zhang, C., Wang, L., and Zhang, H. (2019). Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors. PLoS ONE, 14. 4. Chadha, S.S., Bn, S., Reddy, K., Jaju, J., Ph, V., Rao, S., Parmar, M., Satyanarayana, S., Sachdeva, K.S., and Wilson, N. (2011). Operational Challenges in Diagnosing Multi-Drug Resistant TB and Initiating Treatment in Andhra Pradesh, India. PLoS ONE, 6. 5. Wakjira, M.K., Sandy, P.T., and Mavhandu-Mudzusi, A.H. (2022). Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia. PLoS ONE, 17.
|
|